COMPANY PROFILE // THE 014 REPORT
Werewolf Therapeutics, Inc.
HOWL (Nasdaq)
Assembled from 2 government sources in 2.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-02-06 and 2 more times (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Werewolf Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Waltham, MA; listed as HOWL (Nasdaq).[source] It has filed 154 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are RA CAPITAL MANAGEMENT, L.P., Balyasny Asset Management L.P., VANGUARD CAPITAL MANAGEMENT LLC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 3.01 filed.[source]
- red0
- amber1
- info0
- RA CAPITAL MANAGEMENT, L.P.$859K
- Balyasny Asset Management L.P.$644K
- VANGUARD CAPITAL MANAGEMENT LLC$438K
- RENAISSANCE TECHNOLOGIES LLC$243K
- Lynx1 Capital Management LP$237K
- SPHERA FUNDS MANAGEMENT LTD.$226K
- DC Funds, LP$212K
- Verdad Advisers, LP$126K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Bloom Steven H. · Chief Business Officer (Officer) · latest Form 4 2025-05-02 · filing · LinkedIn search
- Urban Michael J. · VP of Finance & Corp. Contr. (Officer) · latest Form 3 2026-03-13 · filing · LinkedIn search
- Atkins Michael B. · Director · latest Form 4 2025-06-13 · filing · LinkedIn search
- Chatterjee Meeta · Director · latest Form 4 2025-06-13 · filing · LinkedIn search
- EVNIN LUKE · Director · latest Form 4 2026-01-20 · filing · LinkedIn search
- Kolchinsky Peter · Director,10% owner · latest Form 4 2025-05-14 · filing · LinkedIn search
- Lazarus Alon · Director · latest Form 4 2025-06-13 · filing · LinkedIn search
- Morrison Briggs · Director · latest Form 4 2025-06-13 · filing · LinkedIn search
- RA CAPITAL MANAGEMENT, L.P. · Director,10% owner · latest Form 4 2025-05-14 · filing · LinkedIn search
- RA Capital Healthcare Fund LP · Director,10% owner · latest Form 4 2025-05-14 · filing · LinkedIn search
- RA Capital Nexus Fund II, L.P. · Director,10% owner · latest Form 4 2025-05-14 · filing · LinkedIn search
- Shah Rajeev M. · Director,10% owner · latest Form 4 2025-05-14 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Wilmer Cutler Pickering Hale and Dorr LLP · Exhibit 5.1 legal opinion, S-3 filed 2025-05-08
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001785530 | source |
| EIN | 82-3523180 | source |
| Business address (SEC) | 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (7)
- ISKWELAHANG PILIPINO INC · IRS-registered organization
- PROTEUS FUND INC · IRS-registered organization
- NONPROFIT VOTE INC · IRS-registered organization
- PROTEUS ACTION LEAGUE · IRS-registered organization
- THE CONVERSATION US INC · IRS-registered organization
- SPARK PHOTONICS FOUNDATION INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- ARS Pharmaceuticals, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Acrivon Therapeutics, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Acumen Pharmaceuticals, Inc. · Kolchinsky Peter
- Acumen Pharmaceuticals, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Acumen Pharmaceuticals, Inc. · RA Capital Healthcare Fund LP
- Acumen Pharmaceuticals, Inc. · Shah Rajeev M.
- Adicet Bio, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Artiva Biotherapeutics, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Bambusa Therapeutics, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Bicara Therapeutics Inc. · Kolchinsky Peter
- Bicara Therapeutics Inc. · RA CAPITAL MANAGEMENT, L.P.
- Bicara Therapeutics Inc. · RA Capital Healthcare Fund LP
- Bicara Therapeutics Inc. · Shah Rajeev M.
- Cidara Therapeutics, Inc. · RA CAPITAL MANAGEMENT, L.P.
- Climb Bio, Inc. · Kolchinsky Peter
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing EFFECT · SEC EDGAR
- 2026-11-12 filing 424B3 · SEC EDGAR
- 2026-11-10 filing S-4/A · SEC EDGAR
- 2026-11-10 filing 425 · SEC EDGAR
- 2026-11-09 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-26 filing S-4/A · SEC EDGAR
- 2026-09-22 filing S-4 · SEC EDGAR
- 2026-08-21 filing 425 · SEC EDGAR
- 2026-08-21 filing 8-K items 1.01,3.02,7.01,9.01 · SEC EDGAR
- 2026-08-20 filing 8-K items 1.01 · SEC EDGAR
- 2026-07-31 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-31 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-02 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-06-29 filing 144 · SEC EDGAR
- 2026-06-29 filing 144 · SEC EDGAR
- 2026-06-29 filing 144 · SEC EDGAR
- 2026-06-29 filing 144 · SEC EDGAR
- 2026-06-29 filing 144 · SEC EDGAR
- 2026-06-29 filing 144 · SEC EDGAR
- 2026-06-26 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-06-22 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-06-15 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-28 filing 144 · SEC EDGAR
170 earlier entries
- 2026-05-28 filing 144
- 2026-05-28 filing 144
- 2026-05-28 filing 144
- 2026-05-28 filing 144
- 2026-05-28 filing 144
- 2026-05-18 filing 144
- 2026-05-18 filing 144
- 2026-05-18 filing 144
- 2026-05-18 filing 144
- 2026-05-18 filing 144
- 2026-05-18 filing 144
- 2026-05-14 filing SCHEDULE 13D/A
- 2026-05-12 filing SCHEDULE 13D/A
- 2026-05-11 filing 144
- 2026-05-11 filing 144
- 2026-05-11 filing 144
- 2026-05-11 filing 144
- 2026-05-11 filing 144
- 2026-05-11 filing 144
- 2026-05-07 filing Quarterly report (10-Q)
- 2026-05-07 filing 8-K items 2.02,9.01
- 2026-05-05 filing SCHEDULE 13D/A
- 2026-05-01 filing 144
- 2026-05-01 filing 144
- 2026-05-01 filing 144
- 2026-05-01 filing 144
- 2026-05-01 filing 144
- 2026-05-01 filing 144
- 2026-04-29 filing 144
- 2026-04-29 filing 144
- 2026-04-29 filing 144
- 2026-04-29 filing 144
- 2026-04-29 filing 144
- 2026-04-29 filing 144
- 2026-04-27 filing 144
- 2026-04-27 filing 144
- 2026-04-27 filing 144
- 2026-04-27 filing 144
- 2026-04-27 filing 144
- 2026-04-27 filing 144
- 2026-03-27 filing Annual report (10-K)
- 2026-03-27 filing 8-K items 2.02,9.01
- 2026-03-13 insider First Form 3/4/5 on record for Urban Michael J. (VP of Finance & Corp. Contr.)
- 2026-02-24 filing 8-K items 8.01,9.01
- 2026-02-13 officer change 8-K items 2.05,5.02,7.01
- 2026-02-06 filing 8-K items 3.01
- 2026-01-16 filing SCHEDULE 13D/A
- 2026-01-06 filing 144
- 2026-01-06 filing 144
- 2026-01-06 filing 144
- 2026-01-06 filing 144
- 2026-01-06 filing 144
- 2026-01-06 filing 144
- 2025-12-29 filing SCHEDULE 13D/A
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-12-29 filing 144
- 2025-12-22 filing 144
- 2025-12-22 filing 144
- 2025-12-22 filing 144
- 2025-12-22 filing 144
- 2025-12-22 filing 144
- 2025-12-22 filing 144
- 2025-12-18 filing 8-K items 8.01,9.01
- 2025-12-10 filing 144
- 2025-12-10 filing 144
- 2025-12-10 filing 144
- 2025-12-10 filing 144
- 2025-12-10 filing 144
- 2025-12-10 filing 144
- 2025-12-03 filing SCHEDULE 13D/A
- 2025-12-03 filing 144
- 2025-12-03 filing 144
- 2025-12-03 filing 144
- 2025-12-03 filing 144
- 2025-12-03 filing 144
- 2025-12-03 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-24 filing 144
- 2025-11-17 filing SCHEDULE 13D/A
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-10 filing 144
- 2025-11-10 filing 144
- 2025-11-10 filing 144
- 2025-11-10 filing 144
- 2025-11-10 filing 144
- 2025-11-10 filing 144
- 2025-11-06 filing SCHEDULE 13D/A
- 2025-11-04 filing SCHEDULE 13D/A
- 2025-11-04 filing 144
- 2025-11-04 filing 144
- 2025-11-04 filing 144
- 2025-11-04 filing 144
- 2025-11-04 filing 144
- 2025-11-04 filing 144
- 2025-11-04 filing Quarterly report (10-Q)
- 2025-11-04 filing 8-K items 2.02,9.01
- 2025-10-30 filing 144
- 2025-10-30 filing 144
- 2025-10-30 filing 144
- 2025-10-30 filing 144
- 2025-10-30 filing 144
- 2025-10-30 filing 144
- 2025-10-27 filing 144
- 2025-10-27 filing 144
- 2025-10-27 filing 144
- 2025-10-27 filing 144
- 2025-10-27 filing 144
- 2025-10-27 filing 144
- 2025-10-06 filing 8-K items 3.01
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-08-14 filing 8-K items 2.02,7.01,9.01
- 2025-06-13 filing 8-K items 5.03,5.07,9.01
- 2025-06-13 insider First Form 3/4/5 on record for Atkins Michael B. (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Chatterjee Meeta (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Lazarus Alon (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Morrison Briggs (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Sherman Michael A. (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Singhal Anil K. (Director)
- 2025-05-15 filing EFFECT
- 2025-05-15 filing 8-K items 3.01
- 2025-05-14 filing SCHEDULE 13D/A
- 2025-05-14 insider First Form 3/4/5 on record for Kolchinsky Peter (Director,10% owner)
- 2025-05-14 insider First Form 3/4/5 on record for RA CAPITAL MANAGEMENT, L.P. (Director,10% owner)
- 2025-05-14 insider First Form 3/4/5 on record for RA Capital Healthcare Fund LP (Director,10% owner)
- 2025-05-14 insider First Form 3/4/5 on record for RA Capital Nexus Fund II, L.P. (Director,10% owner)
- 2025-05-14 insider First Form 3/4/5 on record for Shah Rajeev M. (Director,10% owner)
- 2025-05-13 filing CORRESP
- 2025-05-12 filing UPLOAD
- 2025-05-08 filing S-3
- 2025-05-08 filing S-8
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,7.01,9.01
- 2025-04-30 insider First Form 3/4/5 on record for EVNIN LUKE (Director)
- 2025-04-28 filing ARS
- 2025-04-28 filing DEFA14A
- 2025-04-28 filing Proxy statement
- 2025-04-18 insider First Form 3/4/5 on record for Bloom Steven H. (Chief Business Officer)
- 2025-03-11 filing 424B5
- 2025-03-11 filing S-8
- 2025-03-11 filing Annual report (10-K)
- 2025-03-11 filing 8-K items 2.02,9.01
- 2025-02-24 officer change 8-K items 5.02
- 2024-11-12 filing 8-K items 7.01,9.01
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,8.01,9.01
- 2024-08-08 filing S-8 POS
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-06-25 filing 8-K items 7.01,8.01,9.01
- 2024-06-03 filing 8-K items 7.01,8.01,9.01
- 2024-05-28 filing 8-K items 5.07
- 2024-05-07 filing SC 13D/A
- 2024-05-03 filing Quarterly report (10-Q)
- 2024-05-03 filing 8-K items 2.02,9.01
- 2024-04-12 filing ARS
- 2024-04-12 filing DEFA14A
- 2024-04-12 filing Proxy statement
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-11-12 (within 30 days) EFFECT filed
- 2026-11-12 (within 30 days) 424B3 filed
- 2026-11-10 (within 30 days) S-4/A filed
- 2026-11-10 (within 30 days) 425 filed
- 2026-11-09 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-26 (within 30 days) S-4/A filed (REGISTRATION OF SECURITIES ISSUED IN BUSINESS COMBINATION TRANSACTIONS)
- 2026-09-22 (older) S-4 filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:HOWL The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
3 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1785530 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | HOWL / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 823523180 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001785530 | SEC EDGAR / IRS |
| CUSIP | 95075A107 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001785530 | SEC EDGAR |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070525307 (WEREWOLF THERAPEUTICS) | name-exact: exact name match to 'Werewolf Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110071307424 (WEREWOLF THERAPEUTICS) | name-exact: exact name match to 'Werewolf Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$60,822,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 09:55 UTC | Report an error |
| Total assets (at 2025-12-31) | $69,396,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 09:55 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $24,805,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 09:55 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $57,050,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 09:55 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:55 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:55 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:55 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:55 UTC | Report an error |
| Business address | 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:55 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:55 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$60,292,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 09:55 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 09:55 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $32,085,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-22 09:55 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $9,435,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 09:55 UTC | Report an error |
| Form D total offering amount (D filed 2021-01-07) | $72,069,999 | 2021-01-07 | D | as filed | 2026-11-22 09:55 UTC | Report an error |
| Form D total amount sold (D filed 2021-01-07) | $72,069,999 | 2021-01-07 | D | as filed | 2026-11-22 09:55 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2021-01-07 | D | as filed | 2026-11-22 09:55 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2021-01-07 | D | as filed | 2026-11-22 09:55 UTC | Report an error |
| Form D date of first sale | 2020-12-23 | 2021-01-07 | D | as filed | 2026-11-22 09:55 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001785530-26-000022
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$9,877,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001785530-26-000022 | 2026-11-22 09:55 UTC | Report an error |
| Interest expense | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001785530-26-000022 | 2026-11-22 09:55 UTC | Report an error |
| Cash and cash equivalents | $41,870,000 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001785530-26-000022 | 2026-11-22 09:55 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $14,400,000 | at 2026-03-31 | 10-Q | 2026-05-07 | 0001785530-26-000012 | 2026-11-22 09:55 UTC | Report an error |
| Debt due in year 2 (from an earlier report) | $8,085,000 | at 2026-03-31 | 10-Q | 2026-05-07 | 0001785530-26-000012 | 2026-11-22 09:55 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 10-Q filed
- 2026-11-12 Filing EFFECT filed
- 2026-11-12 Filing 424B3 filed
- 2026-11-10 Filing S-4/A filed
- 2026-11-10 Filing 425 filed
- 2026-11-09 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-26 Filing S-4/A filed (REGISTRATION OF SECURITIES ISSUED IN BUSINESS COMBINATION TRANSACTIONS)
- 2026-09-22 Filing S-4 filed
- 2026-08-21 Filing 425 filed
- 2026-08-21 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-20 Filing 8-K filed: Item 1.01 material agreement
- 2026-07-31 Filing 10-Q filed
- 2026-07-31 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-27 Filing 10-K filed
- 2026-03-27 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-02-24 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-02-13 Filing 8-K filed: Item 2.05 exit or disposal costs; Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure
- 2026-02-06 Filing 8-K filed: Item 3.01 delisting notice
- 2025-12-18 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-11-04 Filing 10-Q filed
- 2025-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-10-06 Filing 8-K filed: Item 3.01 delisting notice
- 2025-08-14 Filing 10-Q filed
8-K item text, as filed (excerpts)
- 2026-07-31 8-K Item 2.02, Results of Operations and Financial Condition
On July 31, 2026, Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as… the 8-K · retrieved 2026-11-22 09:55 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchWEREWOLF THERAPEUTICS · exact name match to 'Werewolf Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110070525307 Compare
- possible matchWEREWOLF THERAPEUTICS · exact name match to 'Werewolf Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110071307424 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $859,349 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 2 | Balyasny Asset Management L.P. | $644,253 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $438,471 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 4 | RENAISSANCE TECHNOLOGIES LLC | $242,800 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 5 | Lynx1 Capital Management LP | $236,737 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 6 | SPHERA FUNDS MANAGEMENT LTD. | $225,589 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 7 | DC Funds, LP | $212,018 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 8 | Verdad Advisers, LP | $125,500 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $120,895 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
| 10 | BANK OF AMERICA CORP /DE/ | $111,829 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:55 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchWerewolf Therapeutics, Inc. · exact legal name · sx:ctgov:h2e86e6a63314bca0 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1785530.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001785530. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.